Skip to main content Help with accessibility Skip to main navigation

Recommendations

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice. In the absence of any COVID-specific advice then the usual Pan Mersey guidance and RAG rating will still apply unless otherwise indicated.

This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.

Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.

Definitions and Criteria for Categorisation of Medicines

Documents

Date Added: 07 - Jun - 2017

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of antioxidant supplements based on the AREDS or AREDS2 formulae for patients with age related macular degeneration.

Static

Body System:
Date Added: 04 - May - 2020

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of BROLUCIZUMAB solution for injection (Beovu®▼) for neovascular (wet) age-related macular degeneration.

Body System:
Date Added: 25 - Sep - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of CICLOSPORIN 1mg/mL eye drops (Verkazia®), by specialists only, for the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.

Body System:
Date Added: 30 - Jan - 2020

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of FLUOCINOLONE intravitreal implant (Iluvien®) for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy, in accordance with NICE TA613

Body System:
Date Added: 25 - Sep - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of FLUOCINOLONE intravitreal implant (Iluvien®), by specialists only, for the treatment of recurrent non-infectious uveitis in accordance with NICE TA590.

Body System:
Date Added: 25 - Sep - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of RANIBIZUMAB intravitreal injection (Lucentis®), by ophthalmologists only, for the treatment of visual impairment secondary to choroidal neovascularisation (CNV) in conditions not covered by NICE technology appraisals.

Static

Body System:
Date Added: 19 - Dec - 2019

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of RANIBIZUMAB solution for injection (Lucentis®) for the treatment of proliferative diabetic retinopathy.

Body System: